Overview

Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
This is a pilot investigational study of the appropriate therapeutic regimens to treat subjects experiencing inflammatory recurrence (rebound) of psoriatic disease upon discontinuation of efalizumab therapy and of the biological mechanisms involved in inflammatory disease recurrence and control.
Phase:
Phase 4
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Cyclosporine
Cyclosporins
Methotrexate